Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DEK Vaccines
Accra, Ghana
- Ownership
- Private
- Development stage
- Other
01
Overview
No clinical results reported directly. Initial products will use fill-and-finish of WHO-prequalified or established vaccines like R21 malaria vaccine, HPV, pentavalent, and oral cholera vaccine. Tech transfer agreements and partnerships (e.g., with IVI/EuBiologics) underway for product supply in Africa. Facility under construction and planned to deliver first commercial batches in 2025[1][3][4].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccinemRNA-based drugsProtein
- Industry
- Biotech
02
Partnerships
Serum Institute of IndiaInternational Vaccine Institute (IVI)EuBiologicsGovernment of Ghana (National Vaccine Institute)
Beyond the preview
Go deeper on DEK Vaccines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEK Vaccines.